NCT05693766View on ClinicalTrials.gov

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2037

Conditions
Invasive Mammary CarcinomaMetastatic Breast Cancer
Interventions
DRUG

Capecitabine

2000 mg taken by mouth twice daily for 7 days on, 7 days off

OTHER

Endocrine-therapy

Endocrine therapy administered

OTHER

MammoPrint ® and BluePrint assays

Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays

Trial Locations (2)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Agendia
All Listed Sponsors
collaborator

Agendia

INDUSTRY

collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

lead

Sonya Reid

OTHER

NCT05693766 - Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | Biotech Hunter | Biotech Hunter